Becton, Dickinson and Company completes Waters spin‑off, pivots to focused pure‑play medtech
- BD completed spin‑off combining Biosciences with Waters, received about $4.0B, and pivoted to a focused medtech strategy.
- BD will allocate roughly $2.0B to accelerated share repurchases and $2.0B to repay debt, preserving financial flexibility.
- BD announced $110M Neopak syringe investment, gained FDA 510(k) for EnCor EnCompass, and affirmed fiscal‑2026 guidance.
BD completes spin-off with Waters, pivots to pure‑play medtech strategy
Franklin Lakes, N.J. — Becton, Dickinson and Company completes the previously announced spin‑off of its Biosciences & Diagnostic Solutions business and combines that unit with Waters Corporation, a move the company says completes its transformation into a focused medtech operator. BD receives about $4.0 billion in cash from the transaction and says it will “fully pivot to New BD,” intensifying commercial capabilities, accelerating innovation and applying its “BD Excellence” program to drive productivity and gross‑margin expansion.
Management frames the deal as the culmination of BD’s multi‑year BD 2025 strategy to divest non‑core assets and reshape the company around high‑recurring consumables and connected devices. CEO Tom Polen emphasizes opportunities from smarter connected devices, artificial intelligence, and the shift of care into outpatient and home settings, saying the company is positioned to strengthen commercialization and deliver durable revenue and cash‑flow growth. BD also affirms fiscal 2026 revenue guidance and provides adjusted diluted EPS guidance for the refocused New BD, noting first‑quarter results that include $5.3 billion in revenue and adjusted diluted EPS of $2.91.
The company outlines near‑term capital deployment of the transaction proceeds, planning to allocate roughly $2.0 billion to an accelerated share repurchase and $2.0 billion to repay debt, steps it says will be executed subject to market conditions. BD’s leadership highlights the strategic rationale for the split: a leaner balance sheet, sharper operational focus on medtech franchises and a recurring consumables model that underpins future cash generation and investment in product development.
Operational moves and product development
BD continues to advance product and commercial initiatives for the New BD. The company announces a $110 million investment to build BD Neopak glass prefillable syringe capacity in Columbus, Nebraska to support biologic and GLP‑1 drug delivery and U.S. pharmaceutical reshoring. It also expands a partnership with Ypsomed on a 5.5 mL Neopak XtraFlow syringe and gains FDA 510(k) clearance for the EnCor EnCompass breast biopsy and tissue removal system. Other initiatives include a Medical Essentials collaboration to pair BD HD Check rapid point‑of‑care testing with ChemoGLO LC‑MS/MS analysis and the first U.S. hospital implementation of BD Alaris EMR infusion interoperability with MEDITECH.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

